BCL2 and diffuse large B-cell lymphoma: From this perspective, therapeutic approaches making the anti-apoptotic pathway activated, such as inhibition of BCL2, might confer reversal of drug-resistance and further improve survival outcomes of patients with DLBCL treated with R-CHOP.